Syndróm vysadenia antiandrogénov: pokles sérových hladín prostatického specifického antigénu po vysazení antiandrogénov
[The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens]
Language Slovak Country Czech Republic Media print
Document type English Abstract, Journal Article
PubMed
9471771
- MeSH
- Androgen Antagonists administration & dosage MeSH
- Flutamide administration & dosage MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Prostatic Neoplasms immunology therapy MeSH
- Orchiectomy MeSH
- Prostate-Specific Antigen blood MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Names of Substances
- Androgen Antagonists MeSH
- Flutamide MeSH
- Prostate-Specific Antigen MeSH
Combined androgen blockade using surgical or medical (luteinizing hormone-releasing hormone agonist) castration in association with anti-androgen has become the primary therapy in patients with metastatic prostate cancer. Patients undergoing combined androgen blockade will progress within 18-30 months after initial hormonal therapy. When progression occurs following combined androgen blockade, the non-steroid anti-androgen should be subsequently withdrawn. Several recent reports have been published on the paradoxical effect of anti-androgen withdrawal. Eight (22.9%) of 35 patients showed a decline in PSA levels following flutamide withdrawal. The mean time to progression following combined androgen blockade was 26 month and the mean duration of response to flutamide withdrawal was 4.1 months.
